VEEV

TentativeAI MemoPost-earnings T+3

Veeva

As of 2026-08-31/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-31 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 FY2027 beat with improved outlook • 2026-08-26

Base target: $300 / p=55% prob

Biggest risk

The market has already repriced the shares sharply. Falcon adoption, AI monetization, pricing, and technology spending by large biopharma customers remain execution risks; a slowdown could produce meaningful multiple compression.

Invalidation

Break below $225 or thesis failure.

What would change my mind?

The earnings release supports a constructive view: revenue growth accelerated to 18%, subscription revenue grew 16%, profitability remained strong, and management cited record Vault CRM performance plus rapid AI and Falcon progress. [#SEC-8K-2026-08-26]

Research note

Recommendation

—

Confidence

high

As of

2026-08-31

Base target

$300

p=55%

Bull target

$340

p=25%

Bear target

$225

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings re-rating increases valuation sensitivity
Vault CRM and Falcon adoption milestones
The earnings release supports a constructive view: revenue growth accelerated to 18%, subscription revenue grew 16%, profitability remained strong, and management cited record Vault CRM performance plus rapid AI and Falcon progress.

BearKey bullets

Falcon and Vault AI adoption or monetization may lag expectations.
Large-pharma technology spending could slow after mergers or budget reprioritization.
Premium valuation raises downside if revenue growth, margins, or guidance decelerate.

WatchKey bullets

Q2 FY2027 beat with improved outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $300 (p=55%)

Target spread vs base: +13% / -25%

Scenario probabilities

Bull Target: $340 (p=25%)Base Target: $300 (p=55%)Bear Target: $225 (p=20%)

Commentary

News tone is strongly positive following the earnings beat, higher guidance, AI commentary, and reported sharp post-print price reaction. Analyst revisions and detailed target changes are unavailable, and no usable social coverage was provided; confidence therefore rests mainly on company and SEC earnings evidence rather than broad confirmation.

As of 2026-08-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings re-rating increases valuation sensitivity
Vault CRM and Falcon adoption milestones

Scenarios

Bull Target (Scenario probability)

$340 / p=25% prob

Base Target (Scenario probability)

$300 / p=55% prob

Bear Target (Scenario probability)

$225 / p=20% prob

Analysis 2026-08-31 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.80

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-26
Q2 FY2027 beat with improved outlook
Veeva reported Q2 revenue of $928.0M, up 18% year over year, subscription revenue up 16%, operating income up 40%, and said results exceeded guidance. Management provided Q3 revenue guidance of $932M-$935M and FY2027 revenue guidance of $3.68B-$3.69B. [#SEC-8K-2026-08-26] [#8-K-2026-08-26]
Prob 85.00% • Move 8.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Post-earnings re-rating increases valuation sensitivity
2026-09-30
The stock had reportedly risen 15.2% in one day and 40.22% over 30 days after the earnings update. Secondary context cited a 45.2x P/E versus 27.9x for the global healthcare-services industry, leaving limited room for slower growth or weaker Falcon adoption. [#PR-EARNINGS-2026-08-28]
Prob 60% • Move -12% • Priced-in 90%

Long-term Catalysts

Months to a year

Vault CRM and Falcon adoption milestones
2026-12-31
Vault CRM exceeded 180 customers live, including five top-20 biopharmas, with 12 top-20 commitments globally. Veeva Falcon had five early adopters and was on track for initial go-lives in 2026, providing a measurable test of the AI strategy. [#SEC-8K-2026-08-26]
Prob 65% • Move 15% • Priced-in 55%

Risks

Falcon and Vault AI adoption or monetization may lag expectations.
Large-pharma technology spending could slow after mergers or budget reprioritization.
Premium valuation raises downside if revenue growth, margins, or guidance decelerate.
Recent officer open-market sales may create a sentiment overhang, although insider activity is not direct evidence of operating performance. [#SEC-FORM4-2026-08-17]

Peers

Symbol	Summary
CRM	Veeva identifies Salesforce as its primary CRM competitor and notes its life-sciences-specific CRM application, making it a direct functional comparator, although Salesforce has a much broader enterprise software portfolio. [#10-K-2026-03-20]
IQV	Veeva identifies IQVIA as a competitor in CRM, data, analytics, and selected life-sciences applications. It is a direct sector comparator, but its mixed services, data, and software model limits pure-play comparability. [#10-K-2026-03-20]
ORCL	Veeva identifies Oracle as a competitor across selected Development Cloud, Quality Cloud, Commercial Cloud, and legacy-system replacement opportunities. Oracle is a relevant enterprise-software comparator but is substantially more diversified. [#10-K-2026-03-20]

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-31

Loading AI feed…

Symbol

Summary

CRM

Veeva identifies Salesforce as its primary CRM competitor and notes its life-sciences-specific CRM application, making it a direct functional comparator, although Salesforce has a much broader enterprise software portfolio. [#10-K-2026-03-20]

IQV

Veeva identifies IQVIA as a competitor in CRM, data, analytics, and selected life-sciences applications. It is a direct sector comparator, but its mixed services, data, and software model limits pure-play comparability. [#10-K-2026-03-20]

ORCL

Veeva identifies Oracle as a competitor across selected Development Cloud, Quality Cloud, Commercial Cloud, and legacy-system replacement opportunities. Oracle is a relevant enterprise-software comparator but is substantially more diversified. [#10-K-2026-03-20]